Immortalization capacity of HPV types is inversely related to chromosomal instability

Oncotarget

Volumn 7, Issue 25, 2016, Pages 37608-37621

  Schütze, Denise M ^a   Krijgsman, Oscar ^b   Snijders, Peter J F ^a   Ylstra, Bauke ^a   Weischenfeldt, Joachim ^c   Mardin, Balca R ^c   Stütz, Adrian M ^c   Korbel, Jan O ^c   de Winter, Johan P ^a   Meijer, Chris J L M ^a   Quint, Wim G V ^d   Bosch, Leontien ^a   Wilting, Saskia M ^a   Steenbergen, Renske D M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

^d DDL DIAGNOSTIC LABORATORY   (Netherlands)

Author keywords

ArrayCGH; Chromothripsis; E6 E7; High risk HPV; Transformation

Indexed keywords

DOUBLE STRANDED DNA; MYC PROTEIN; TELOMERASE REVERSE TRANSCRIPTASE;

ARTICLE; CELL IMMORTALIZATION; CHROMOSOMAL INSTABILITY; CHROMOSOME 5P; CHROMOSOME 8; CHROMOSOME ABERRATION; CHROMOSOME REARRANGEMENT; CHROMOTHRIPSIS; DNA DAMAGE; DOUBLE STRANDED DNA BREAK; GENE LOCUS; GENOMIC INSTABILITY; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 51; HUMAN PAPILLOMAVIRUS TYPE 59; HUMAN PAPILLOMAVIRUS TYPE 66; HUMAN PAPILLOMAVIRUS TYPE 70; KERATINOCYTE; NONHUMAN; PAPILLOMAVIRIDAE; PREPUCE; PROTEIN EXPRESSION; PROTEIN INDUCTION; VIRUS TYPING; WART VIRUS; GENETICS; METABOLISM; PAPILLOMAVIRUS INFECTION; VIROLOGY;

CHROMOSOMAL INSTABILITY; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; PAPILLOMAVIRUS INFECTIONS;

EID: 84964392846     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.8058     Document Type: Article

References (43)

1. IARC. Biological agents. Volume 100 B. A review of human carcinogens. IARC Monogr Eval Carcinog Risks Hum. 2012; 100:1-441.
2. Steenbergen RD, Snijders PJ, Heideman DA, Meijer CJ. Clinical implications of (epi)genetic changes in HPVinduced cervical precancerous lesions. Nature Reviews Cancer. 2014; 14:395-405.
3. Steenbergen RD, de Wilde J, Wilting SM, Brink AA, Snijders PJ, Meijer CJ. HPV-mediated transformation of the anogenital tract. J Clin Virol. 2005; 32 Suppl 1:S25-33.
4. Duensing S, Münger K. The human papillomavirus type 16 E6 and E7 oncoproteins independently induce numerical and structural chromosome instability. Cancer Res. 2002; 62:7075-7082.
5. Spardy N, Covella K, Cha E, Hoskins EE, Wells SI, Duensing A, Duensing S. Human papillomavirus 16 E7 oncoprotein attenuates DNA damage checkpoint control by increasing the proteolytic turnover of claspin. Cancer Res. 2009; 69:7022-7029.
6. Steenbergen RD, Walboomers JM, Meijer CJ, van der Raaij-Helmer EM, Parker JN, Chow LT, Broker TR, Snijders PJ. Transition of human papillomavirus type 16 and 18 transfected human foreskin keratinocytes towards immortality: activation of telomerase and allele losses at 3p, 10p, 11q and/or 18q. Oncogene. 1996; 13:1249-1257.
7. Klingelhutz AJ, Barber SA, Smith PP, Dyer K, McDougall JK. Restoration of telomeres in human papillomavirusimmortalized human anogenital epithelial cells. Mol Cell Biol. 1994; 14:961-969.
8. Cottage A, Dowen S, Roberts I, Pett M, Coleman N, Stanley M. Early genetic events in HPV immortalised keratinocytes. Genes Chromosomes Cancer. 2001; 30:72-79.
9. Steenbergen RD, Hermsen MA, Walboomers JM, Meijer GA, Baak JP, Meijer CJ, Snijders PJ. Non-random allelic losses at 3p, 11p and 13q during HPV-mediated immortalization and concomitant loss of terminal differentiation of human keratinocytes. Int J Cancer. 1998; 76:412-417.
10. van Duin M, Steenbergen RD, de Wilde J, Helmerhorst TJ, Verheijen RH, Risse EK, Meijer CJ, Snijders PJ. Telomerase activity in high-grade cervical lesions is associated with allelic imbalance at 6Q14-22. Int J Cancer. 2003; 105:577-582.
11. Duensing A, Spardy N, Chatterjee P, Zheng L, Parry J, Cuevas R, Korzeniewski N, Duensing S. Centrosome overduplication, chromosomal instability, and human papillomavirus oncoproteins. Environ Mol Mutagen. 2009; 50:741-747.
12. Boccardo E. HPV-mediated genome instability: at the roots of cervical carcinogenesis. Cytogenet Genome Res. 2010; 128:57-65.
13. Thomas LK, Bermejo JL, Vinokurova S, Jensen K, Bierkens M, Steenbergen R, Bergmann M, von Knebel Doeberitz M, Reuschenbach M. Chromosomal gains and losses in human papillomavirus-associated neoplasia of the lower genital tract-a systematic review and meta-analysis. Eur J Cancer. 2014; 50:85-98.
14. Schütze DM, Snijders PJ, Bosch L, Kramer D, Meijer CJ, Steenbergen RD. Differential in vitro immortalization capacity of eleven (probable) [corrected] high-risk human papillomavirus types. J Virology. 2014; 88:1714-1724.
15. Schütze DM, Kooter JM, Wilting SM, Meijer CJ, Quint W, Snijders PJ, Steenbergen RD. Longitudinal assessment of DNA methylation changes during HPVE6E7-induced immortalization of primary keratinocytes. Epigenetics. 2015; 10:73-81.
16. Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. Nature Reviews Cancer. 2010; 10:550-560.
17. Muralidhar B, Winder D, Murray M, Palmer R, Barbosa-Morais N, Saini H, Roberts I, Pett M, Coleman N. Functional evidence that Drosha overexpression in cervical squamous cell carcinoma affects cell phenotype and microRNA profiles. J Pathol. 2011; 224:496-507.
18. Snijders PJ, van Duin M, Walboomers JM, Steenbergen RD, Risse EK, Helmerhorst TJ, Verheijen RH, Meijer CJ. Telomerase activity exclusively in cervical carcinomas and a subset of cervical intraepithelial neoplasia grade III lesions: strong association with elevated messenger RNA levels of its catalytic subunit and high-risk human papillomavirus DNA. Cancer Res. 1998; 58:3812-3818.
19. Zhang A, Månér S, Betz R, Angström T, Stendahl U, Bergman F, Zetterberg A, Wallin KL. Genetic alterations in cervical carcinomas: frequent low-level amplifications of oncogenes are associated with human papillomavirus infection. Int J Cancer. 2002; 101:427-433.
20. Stephens PJ, Greenman CD, Fu B, Yang F, Bignell GR, Mudie LJ, Pleasance ED, Lau KW, Beare D, Stebbings LA, McLaren S, Lin ML, McBride DJ, Varela I, Nik-Zainal S, Leroy C, et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell. 2011; 144:27-40.
21. Bester AC, Roniger M, Oren YS, Im MM, Sarni D, Chaoat M, Bensimon A, Zamir G, Shewach DS, Kerem B. Nucleotide deficiency promotes genomic instability in early stages of cancer development. Cell. 2011; 145:435-446.
22. King LE, Fisk JC, Dornan ES, Donaldson MM, Melendy T, Morgan IM. Human papillomavirus E1 and E2 mediated DNA replication is not arrested by DNA damage signalling. Virology. 2010; 406:95-102.
23. Xue Y, Toh SY, He P, Lim T, Lim D, Pang CL, Abastado JP, Thierry F. HPV16-E2 induces prophase arrest and activates the cellular DNA damage response in vitro and in precursor lesions of cervical carcinoma. Oncotarget. 2015; 6:34979-34991. doi: 10.18632/oncotarget.5512.
24. Van Doorslaer K, Burk RD. Association between hTERT activation by HPV E6 proteins and oncogenic risk. Virology. 2012; 433:216-219.
25. Hackett JA, Greider CW. Balancing instability: dual roles for telomerase and telomere dysfunction in tumorigenesis. Oncogene. 2002; 21:619-626.
26. Zhang A, Zheng C, Hou M, Lindvall C, Wallin KL, Angström T, Yang X, Hellström AC, Blennow E, Björkholm M, Zetterberg A, Gruber A, Xu D. Amplification of the telomerase reverse transcriptase (hTERT) gene in cervical carcinomas. Genes Chromosomes Cancer. 2002; 34:269-275.
27. Zhang A, Zheng C, Lindvall C, Hou M, Ekedahl J, Lewensohn R, Yan Z, Yang X, Henriksson M, Blennow E, Nordenskjöld M, Zetterberg A, Björkholm M, Gruber A, Xu D. Frequent amplification of the telomerase reverse transcriptase gene in human tumors. Cancer Res. 2000; 60:6230-6235.
28. Backsch C, Rudolph B, Kühne-Heid R, Kalscheuer V, Bartsch O, Jansen L, Beer K, Meyer B, Schneider A, Dürst M. A region on human chromosome 4 (q35.1->qter) induces senescence in cell hybrids and is involved in cervical carcinogenesis. Genes Chromosomes Cancer. 2005; 43:260-272.
29. Bierkens M, Wilting SM, van Wieringen WN, van Kemenade FJ, Bleeker MC, Jordanova ES, Bekker-Lettink M, van de Wiel MA, Ylstra B, Meijer CJ, Snijders PJ, Steenbergen RD. Chromosomal profiles of high-grade cervical intraepithelial neoplasia relate to duration of preceding high-risk human papillomavirus infection. Int J Cancer. 2012; 131:E579-585.
30. Cuthill S, Agarwal P, Sarkar S, Savelieva E, Reznikoff CA. Dominant genetic alterations in immortalization: role for 20q gain. Genes Chromosomes Cancer. 1999; 26:304-311.
31. Savelieva E, Belair CD, Newton MA, DeVries S, Gray JW, Waldman F, Reznikoff CA. 20q gain associates with immortalization: 20q13.2 amplification correlates with genome instability in human papillomavirus 16 E7 transformed human uroepithelial cells. Oncogene. 1997; 14:551-560.
32. Klingelhutz AJ, Qian Q, Phillips SL, Gourronc FA, Darbro BW, Patil SR. Amplification of the chromosome 20q region is associated with expression of HPV-16 E7 in human airway and anogenital epithelial cells. Virology. 2005; 340:237-244.
33. Lando M, Wilting SM, Snipstad K, Clancy T, Bierkens M, Aarnes EK, Holden M, Stokke T, Sundfor K, Holm R, Kristensen GB, Steenbergen RD, Lyng H. Identification of eight candidate target genes of the recurrent 3p12-p14 loss in cervical cancer by integrative genomic profiling. J Pathol. 2013; 230:59-69.
34. Macville M, Schröck E, Padilla-Nash H, Keck C, Ghadimi BM, Zimonjic D, Popescu N, Ried T. Comprehensive and definitive molecular cytogenetic characterization of HeLa cells by spectral karyotyping. Cancer Res. 1999; 59:141-150.
35. Solinas-Toldo S, Dürst M, Lichter P. Specific chromosomal imbalances in human papillomavirus-transfected cells during progression toward immortality. Proceedings of the National Academy of Sciences of the United States of America. 1997; 94:3854-3859.
36. Dürst M, Seagon S, Wanschura S, zur Hausen H, Bullerdiek J. Malignant progression of an HPV16-immortalized human keratinocyte cell line (HPKIA) in vitro. Cancer Genetics and Cytogenetics. 1995; 85:105-112.
37. Peter M, Rosty C, Couturier J, Radvanyi F, Teshima H, Sastre-Garau X. MYC activation associated with the integration of HPV DNA at the MYC locus in genital tumors. Oncogene. 2006; 25:5985-5993.
38. van Zeeburg HJ, Snijders PJ, Pals G, Hermsen MA, Rooimans MA, Bagby G, Soulier J, Gluckman E, Wennerberg J, Leemans CR, Joenje H, Brakenhoff RH. Generation and molecular characterization of head and neck squamous cell lines of fanconi anemia patients. Cancer Res. 2005; 65:1271-1276.
39. van de Wiel MA, Picard F, van Wieringen WN, Ylstra B. Preprocessing and downstream analysis of microarray DNA copy number profiles. Brief Bioinform. 2011; 12:10-21.
40. Rausch T, Zichner T, Schlattl A, Stütz AM, Benes V, Korbel JO. DELLY: structural variant discovery by integrated paired-end and split-read analysis. Bioinformatics. 2012; 28:i333-i339.
41. Weischenfeldt J, Simon R, Feuerbach L, Schlangen K, Weichenhan D, Minner S, Wuttig D, Warnatz HJ, Stehr H, Rausch T, Jäger N, Gu L, Bogatyrova O, Stütz AM, Claus R, Eils J, et al. Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer Cell. 2013; 23:159-170.
42. Scheinin I, Sie D, Bengtsson H, van de Wiel MA, Olshen AB, van Thuijl HF, van Essen HF, Eijk PP, Rustenburg F, Meijer GA, Reijneveld JC, Wesseling P, Pinkel D, Albertson DG, Ylstra B. DNA copy number analysis of fresh and formalin-fixed specimens by shallow wholegenome sequencing with identification and exclusion of problematic regions in the genome assembly. Genome Res. 2014; 24:2022-2032.
43. van de Wiel MA, Smeets SJ, Brakenhoff RH, Ylstra B. CGHMultiArray: exact P-values for multi-array comparative genomic hybridization data. Bioinformatics. 2005; 21:3193-3194.